Lobbyist Connections in Rep. Bill Huizenga’s Office Draw Scrutiny
Republican Representative Bill Huizenga, who has been serving Michigan’s 4th District since 2011, has seen at least a dozen of his office staff transition into lobbying roles or had prior experience as lobbyists. As he campaigns for a ninth term, these connections are drawing increased attention.
Federal regulations require lobbyists to register and disclose their clientele, and such public filings show Huizenga’s staff members have been involved with the finance, insurance, and pharmaceutical sectors.
Among these staff members is Jon DeWitte, Huizenga’s chief of staff for over ten years, who left in 2022 to become a lobbyist and vice president of government affairs for Travelers Insurance. According to recent disclosures, Travelers has lobbied Congress on health care, trade, opioid, tax, and insurance issues.
Heartland Signal reported in 2023 that Marlis McManus, Huizenga’s former deputy chief of staff, is currently lobbying for the investment firm Vanguard. McManus’s role involves advocating for issues concerning investment funds and equity markets. She previously engaged in lobbying for the National Association of Mutual Insurance Companies before her tenure in Huizenga’s office.
This career path is often described as revolving-door politics, where individuals move between public roles and private sector positions, potentially leading to conflicts of interest and increased corporate influence in legislative processes.
Other notable former staff members turned lobbyists include Palmer Rafferty, who is now with TransUnion, and Martin Van Valkenburg, who had connections with an aerospace company. These businesses fall under the purview of congressional regulation and oversight, particularly significant given Huizenga’s position on the Financial Services Committee.
Adding to the list, at least seven more of Huizenga’s former staffers have entered the lobbying arena, including a senior legislative assistant now representing pharmaceutical giants Bayer, Eli Lilly, and Novartis.
As Huizenga faces re-election, the Democratic Congressional Campaign Committee has marked him as one of the more vulnerable Republicans. His opponent, State Senator Sean McCann, is gearing up for a competitive race.
For more information, visit the original article on American Journal News.
